CTOR — CITIUS ONCOLOGY, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1851484 ·
Last close
$1.05
Market Cap
$111.05M
52W High
$2.25
52W Low
$0.49
ADV30
95,657
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,493,788 | 1,001,945 | -8,716,817 | -8,923,846 | 112,093,103 | 16,563,705 | 71,708,109 |
| Mar 2026 | 1,667,298 | 1,338,420 | -28,613,595 | -26,609,695 | 100,699,168 | 2,632,634 | 65,430,399 |
| Dec 2025 | 3,944,111 | 3,154,903 | -4,678,838 | -5,534,069 | 109,973,406 | 7,295,451 | 51,559,705 |
| Sep 2025 | 0 | — | -4,711,512 | -4,996,656 | 100,942,881 | 3,924,908 | 56,076,650 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-16,678,610
Investing CF
$-5,000,000
Financing CF
$14,894,290
CapEx
$-5,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.52
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-96,183,720
Inventory
$22,659,590
Receivables
$1,079,055
ST Investments
—
EBIT TTM
$-41,651,962
Pretax Income TTM
$-41,948,866
Interest Exp TTM
$296,904
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,105,197
EBITDA
—
Free Cash Flow
$-31,167,442
Enterprise Value
$90,680,432
Total Cash
$16,563,705
Total Debt
$10,210,272
Shares Out
105,758,982
Trailing EPS
$-0.48
Book Value
$0.38
ROE
-126.6%
ROA
-29.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | -23,522,750 | -24,761,369 | 100,942,881 | 56,076,650 | 44,866,231 | -5,492,046 |
| Sep 2024 | 0 | -20,572,747 | -21,148,747 | 84,368,878 | 38,228,539 | 46,140,339 | 126,353 |
| Sep 2023 | 0 | -12,121,241 | -12,697,241 | 47,734,895 | 22,199,235 | 25,535,660 | 0 |
| Sep 2022 | 0 | -4,856,599 | -5,432,599 | 42,690,182 | 6,422,781 | 36,267,401 | 0 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AARD | Aardvark Therapeutics, Inc. | $110.74M | $5.06 | — |
| GNLX | GENELUX Corp | $112.21M | $2.48 | — |
| KZIA | KAZIA THERAPEUTICS LTD | $109.36M | $9.57 | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | $114.02M | $7.61 | — |
| QUCY | Quantum Cyber N.V. | $115.17M | $1.37 | — |
News headlines (Yahoo Finance, 1h cache)
Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum
2026-08-17 12:28 · Yahoo
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
2026-08-12 12:00 · Yahoo
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
2026-08-05 13:17 · Yahoo
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
2026-07-21 13:17 · Yahoo
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
2026-06-01 11:00 · Yahoo
Citius raises $36.5m for Lymphir commercialisation
2026-05-06 13:04 · Yahoo
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
2026-05-06 00:00 · Yahoo
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
2026-04-29 12:00 · Yahoo
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
2026-03-31 13:11 · Yahoo
Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)
2026-04-15 10:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.